Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 4/2017

22.11.2016 | Retinal Disorders

Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension

verfasst von: Sofia Theodoropoulou, Abdallah A. Ellabban, Robert L. Johnston, Helena Cilliers, Quresh Mohamed, Ahmed B. Sallam

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To report the short-term safety of dexamethasone implants to treat macular edema due to retinal vein occlusion (RVO), in eyes with treated glaucoma or ocular hypertension at baseline using an as-needed re-treatment regimen.

Methods

Retrospective clinical database study from two centers using the same electronic medical record system. Extracted data included: intraocular pressure (IOP), visual acuity (VA), central 1 mm retinal thickness (CRT) by optical coherence tomography, phakic status, number of injections, glaucoma treatment, and peri-operative complications.

Results

Thirty-three eyes of 33 patients on IOP-lowering treatment for glaucoma or ocular hypertension (OHT) at baseline and mean IOP of 16 mmHg at baseline received one to four (mean, 1.8; median, 1) dexamethasone implants over 18 months for RVO-related macular edema. Fourteen eyes (42 %) had IOP of ≥21 mmHg, and three eyes (9 %) had IOP of ≥35 mmHg at one or more visits during the study period. Nine of 14 eyes (64 %) with raised IOP required additional topical treatment only for a mean (SE) period of 8.5 months (3.2), while the remaining five eyes (36 %) required long-term additional IOP-lowering treatment for a mean (SE) of 16 months (1.44). Surgery for IOP lowering was not required in any eye. Mean VA (SE) improved from 44 (3) ETDRS letters at baseline to 47 letters (5) at 2 months (p = 0.049), 48 (8) letters at 6 months and 46 (4) letters at 12 months. Mean CRT (SE) improved from 530 (25) μm at baseline to 323 (27) μm at 2 months (p < 0.001), 498 (76) μm at 6 months, and 359 (25) μm at 12 months (p < 0.001).

Conclusion

The short-term IOP rise after intravitreal dexamethasone implant in eyes with glaucoma or ocular hypertension at baseline was acceptable and consistent with previous reports in patients without preexisting glaucoma. Treated OHT or glaucoma may not be a strict contraindication against the use of dexamethasone implant, but close monitoring of IOP is required.
Literatur
1.
Zurück zum Zitat McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, Kowalski JW, Nguyen HP, Wong TY (2010) Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117(6):1113.e1115–1123.e1115. doi:10.1016/j.ophtha.2010.01.060 CrossRef McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, Kowalski JW, Nguyen HP, Wong TY (2010) Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117(6):1113.e1115–1123.e1115. doi:10.​1016/​j.​ophtha.​2010.​01.​060 CrossRef
2.
Zurück zum Zitat Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, Nguyen HP, Wang JJ, Wong TY (2010) Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117(6):1094.e1095–1101.e1095. doi:10.1016/j.ophtha.2010.01.058 CrossRef Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, Nguyen HP, Wang JJ, Wong TY (2010) Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117(6):1094.e1095–1101.e1095. doi:10.​1016/​j.​ophtha.​2010.​01.​058 CrossRef
3.
Zurück zum Zitat The Central Vein Occlusion Study Group M report (1995) Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology 102(10):1425–1433CrossRef The Central Vein Occlusion Study Group M report (1995) Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology 102(10):1425–1433CrossRef
4.
Zurück zum Zitat The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98(3):271–282CrossRef The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98(3):271–282CrossRef
5.
Zurück zum Zitat Shirodkhar AL, Lightman S, Taylor SR (2012) Management of branch retinal vein occlusion. Br J Hosp Med (Lond) 73(1):20–23CrossRef Shirodkhar AL, Lightman S, Taylor SR (2012) Management of branch retinal vein occlusion. Br J Hosp Med (Lond) 73(1):20–23CrossRef
6.
Zurück zum Zitat Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 127(9):1101–1114. doi:10.1001/archophthalmol.2009.234 CrossRefPubMedPubMedCentral Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 127(9):1101–1114. doi:10.​1001/​archophthalmol.​2009.​234 CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134.e1133–1146.e1133. doi:10.1016/j.ophtha.2010.03.032 CrossRef Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134.e1133–1146.e1133. doi:10.​1016/​j.​ophtha.​2010.​03.​032 CrossRef
8.
Zurück zum Zitat Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, Li J (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118(12):2453–2460. doi:10.1016/j.ophtha.2011.05.014 CrossRefPubMed Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, Li J (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118(12):2453–2460. doi:10.​1016/​j.​ophtha.​2011.​05.​014 CrossRefPubMed
9.
Zurück zum Zitat Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118(8):1594–1602. doi:10.1016/j.ophtha.2011.02.022 CrossRefPubMed Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118(8):1594–1602. doi:10.​1016/​j.​ophtha.​2011.​02.​022 CrossRefPubMed
10.
Zurück zum Zitat Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118(10):2041–2049. doi:10.1016/j.ophtha.2011.02.038 CrossRefPubMed Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118(10):2041–2049. doi:10.​1016/​j.​ophtha.​2011.​02.​038 CrossRefPubMed
12.
14.
15.
Zurück zum Zitat Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155(3):429.e427–437.e427. doi:10.1016/j.ajo.2012.09.026 CrossRef Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155(3):429.e427–437.e427. doi:10.​1016/​j.​ajo.​2012.​09.​026 CrossRef
16.
Zurück zum Zitat Zarranz-Ventura J, Carreno E, Johnston RL, Mohammed Q, Ross AH, Barker C, Fonollosa A, Artaraz J, Pelegrin L, Adan A, Lee RW, Dick AD, Sallam A (2014) Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol 158(6):1136.e1135–1145.e1135. doi:10.1016/j.ajo.2014.09.003 CrossRef Zarranz-Ventura J, Carreno E, Johnston RL, Mohammed Q, Ross AH, Barker C, Fonollosa A, Artaraz J, Pelegrin L, Adan A, Lee RW, Dick AD, Sallam A (2014) Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol 158(6):1136.e1135–1145.e1135. doi:10.​1016/​j.​ajo.​2014.​09.​003 CrossRef
17.
Zurück zum Zitat Capone A Jr, Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB, Walt JG, Scott LC, Hollander DA (2014) Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina 34(2):342–351. doi:10.1097/IAE.0b013e318297f842 CrossRefPubMed Capone A Jr, Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB, Walt JG, Scott LC, Hollander DA (2014) Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina 34(2):342–351. doi:10.​1097/​IAE.​0b013e318297f842​ CrossRefPubMed
19.
Zurück zum Zitat Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121(10):1904–1914. doi:10.1016/j.ophtha.2014.04.024 CrossRefPubMed Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121(10):1904–1914. doi:10.​1016/​j.​ophtha.​2014.​04.​024 CrossRefPubMed
20.
21.
Zurück zum Zitat Schmitz K, Maier M, Clemens CR, Hohn F, Wachtlin J, Lehmann F, Bertelmann T, Rudiger K, Horn M, Bezatis A, Spital G, Meyer CH (2014) Reliability and safety of intravitreal Ozurdex injections. The ZERO study. Ophthalmologe 111(1):44–52. doi:10.1007/s00347-012-2737-2 CrossRefPubMed Schmitz K, Maier M, Clemens CR, Hohn F, Wachtlin J, Lehmann F, Bertelmann T, Rudiger K, Horn M, Bezatis A, Spital G, Meyer CH (2014) Reliability and safety of intravitreal Ozurdex injections. The ZERO study. Ophthalmologe 111(1):44–52. doi:10.​1007/​s00347-012-2737-2 CrossRefPubMed
22.
Zurück zum Zitat Coscas G, Augustin A, Bandello F, de Smet MD, Lanzetta P, Staurenghi G, Parravano MC, Udaondo P, Moisseiev E, Soubrane G, Yatziv Y, Loewenstein A (2014) Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 24(1):1–9. doi:10.5301/ejo.5000376 PubMed Coscas G, Augustin A, Bandello F, de Smet MD, Lanzetta P, Staurenghi G, Parravano MC, Udaondo P, Moisseiev E, Soubrane G, Yatziv Y, Loewenstein A (2014) Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 24(1):1–9. doi:10.​5301/​ejo.​5000376 PubMed
23.
Zurück zum Zitat Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, Cascavilla ML, Bandello F (2013) Repeated intravitreal dexamethasone implant (Ozurdex(R)) for retinal vein occlusion. Ophthalmologica 229(1):21–25. doi:10.1159/000342160 CrossRefPubMed Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, Cascavilla ML, Bandello F (2013) Repeated intravitreal dexamethasone implant (Ozurdex(R)) for retinal vein occlusion. Ophthalmologica 229(1):21–25. doi:10.​1159/​000342160 CrossRefPubMed
Metadaten
Titel
Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension
verfasst von
Sofia Theodoropoulou
Abdallah A. Ellabban
Robert L. Johnston
Helena Cilliers
Quresh Mohamed
Ahmed B. Sallam
Publikationsdatum
22.11.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 4/2017
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-016-3553-1

Weitere Artikel der Ausgabe 4/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 4/2017 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Open Access 22.02.2024 | Peeling | Originalien

Selektive Vitalfarbstoffe in der Makulachirurgie

Erhöhen sie die Wahrscheinlichkeit der intraoperativen ILM-Identifizierung auch bei einem erfahrenen Operateur?

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.